Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases—Current State of the Art
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases—Current State of the Art
Authors
Keywords
-
Journal
Cells
Volume 9, Issue 1, Pages 129
Publisher
MDPI AG
Online
2020-01-06
DOI
10.3390/cells9010129
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Kinetic network model to explain gain-of-function mutations in ERK2 enzyme
- (2019) Mikita Misiura et al. JOURNAL OF CHEMICAL PHYSICS
- Current status and future perspective of robot‐assisted radical cystectomy for invasive bladder cancer
- (2019) Tetsuya Fujimura INTERNATIONAL JOURNAL OF UROLOGY
- Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2
- (2019) Laurel M. Pegram et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functional divergence caused by mutations in an energetic hotspot in ERK2
- (2019) Clinton A. Taylor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ancestral reconstruction reveals mechanisms of ERK regulatory evolution
- (2019) Dajun Sang et al. eLife
- An Activating Mutation in ERK Causes Hyperplastic Tumors in a scribble Mutant Tissue in Drosophila
- (2019) Tatyana Kushnir et al. GENETICS
- Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies
- (2019) Lei Yang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Extracellular signal-regulated kinase (ERK) activation preserves cardiac function in pressure overload induced hypertrophy
- (2018) Michael Mutlak et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
- (2018) Feifei Liu et al. Acta Pharmaceutica Sinica B
- Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- G protein–coupled receptor kinases (GRKs) orchestrate biased agonism at the β2-adrenergic receptor
- (2018) Minjung Choi et al. Science Signaling
- Therapeutic strategies to target RAS-mutant cancers
- (2018) Meagan B. Ryan et al. Nature Reviews Clinical Oncology
- Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
- (2017) Ursula A. Germann et al. MOLECULAR CANCER THERAPEUTICS
- Allosteric MEK1/2 inhibitors including cobimetanib and trametinib in the treatment of cutaneous melanomas
- (2017) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
- (2017) et al. Cancers
- Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
- (2016) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- Variants of the yeast MAPK Mpk1 are fully functional independently of activation loop phosphorylation
- (2016) Tal Goshen-Lago et al. MOLECULAR BIOLOGY OF THE CELL
- Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylation
- (2016) Karina Smorodinsky-Atias et al. MOLECULAR BIOLOGY OF THE CELL
- Dissecting Therapeutic Resistance to ERK Inhibition
- (2016) S. Jha et al. MOLECULAR CANCER THERAPEUTICS
- How Do Protein Kinases Take a Selfie (Autophosphorylate)?
- (2016) Jonah Beenstock et al. TRENDS IN BIOCHEMICAL SCIENCES
- Phenotypic Characterization of a Comprehensive Set of MAPK1 /ERK2 Missense Mutants
- (2016) Lisa Brenan et al. Cell Reports
- Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes
- (2015) Ana Herrero et al. CANCER CELL
- Dynamics-Driven Allostery in Protein Kinases
- (2015) Alexandr P. Kornev et al. TRENDS IN BIOCHEMICAL SCIENCES
- Functional Redundancy of ERK1 and ERK2 MAP Kinases during Development
- (2015) Christophe Frémin et al. Cell Reports
- LPS-Induced G-CSF Expression in Macrophages Is Mediated by ERK2, but Not ERK1
- (2015) Shwu-Fen Chang et al. PLoS One
- ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
- (2014) E. M. Goetz et al. CANCER RESEARCH
- Transmembrane signaling in Saccharomyces cerevisiae as a model for signaling in metazoans: State of the art after 25years
- (2014) David Engelberg et al. CELLULAR SIGNALLING
- Recent Progress in the Design, Study, and Development of c-Jun N-Terminal Kinase Inhibitors as Anticancer Agents
- (2014) Abdellah Messoussi et al. CHEMISTRY & BIOLOGY
- The regulation and functions of MAPK pathways in Drosophila
- (2014) Ben-Zion Shilo METHODS
- Drug resistance to targeted therapies: Déjà vu all over again
- (2014) Floris H. Groenendijk et al. Molecular Oncology
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- Hog1: 20 years of discovery and impact
- (2014) J. L. Brewster et al. Science Signaling
- Receptor Tyrosine Kinases: Legacy of the First Two Decades
- (2014) J. Schlessinger Cold Spring Harbor Perspectives in Biology
- ERK2 but not ERK1 mediates HGF-induced motility in non-small cell lung carcinoma cell lines
- (2013) S. Radtke et al. JOURNAL OF CELL SCIENCE
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- Mammalian MAPK Signal Transduction Pathways Activated by Stress and Inflammation: A 10-Year Update
- (2012) John M. Kyriakis et al. PHYSIOLOGICAL REVIEWS
- Importance of Domain Closure for the Autoactivation of ERK2
- (2011) Daniel Barr et al. BIOCHEMISTRY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Strong negative feedback from Erk to Raf confers robustness to MAPK signalling
- (2011) R. Fritsche-Guenther et al. Molecular Systems Biology
- The MAPK ERK1 is a negative regulator of the adult steady-state splenic erythropoiesis
- (2010) S. Guihard et al. BLOOD
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Regulation of cross-talk in yeast MAPK signaling pathways
- (2010) Haruo Saito CURRENT OPINION IN MICROBIOLOGY
- Genetic Demonstration of a Redundant Role of Extracellular Signal-Regulated Kinase 1 (ERK1) and ERK2 Mitogen-Activated Protein Kinases in Promoting Fibroblast Proliferation
- (2010) L. Voisin et al. MOLECULAR AND CELLULAR BIOLOGY
- ERK2 but Not ERK1 Induces Epithelial-to-Mesenchymal Transformation via DEF Motif-Dependent Signaling Events
- (2010) Sejeong Shin et al. MOLECULAR CELL
- ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
- (2010) Fumin Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer
- (2009) Hae-Young Yong et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway
- (2009) S.-Y. Shin et al. JOURNAL OF CELL SCIENCE
- Structure-Guided Design of Potent and Selective Pyrimidylpyrrole Inhibitors of Extracellular Signal-Regulated Kinase (ERK) Using Conformational Control
- (2009) Alex M. Aronov et al. JOURNAL OF MEDICINAL CHEMISTRY
- Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within theDUSP6/MKP-3gene promoter
- (2008) Maria Ekerot et al. BIOCHEMICAL JOURNAL
- Small Molecule p38 MAP Kinase Inhibitors for the Treatment of Inflammatory Diseases: Novel Structures and Developments During 2006- 2008
- (2008) Liping Pettus et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Activation segment dimerization: a mechanism for kinase autophosphorylation of non-consensus sites
- (2008) Ashley C W Pike et al. EMBO JOURNAL
- Specificity of signaling from MAPKs to MAPKAPKs: Kinases' Tango Nuevo
- (2008) Matthias Gaestel Frontiers in Bioscience-Landmark
- Isolation of Intrinsically Active (MEK-independent) Variants of the ERK Family of Mitogen-activated Protein (MAP) Kinases
- (2008) Vered Levin-Salomon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Deletion of ERK2 Mitogen-Activated Protein Kinase Identifies Its Key Roles in Cortical Neurogenesis and Cognitive Function
- (2008) I. S. Samuels et al. JOURNAL OF NEUROSCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started